I checked the CVAS message board, apparentlly, prior to the deal there was not much faith in the phase II trial, but it had already been funded. With DNDN in control they will do what ever is necessary, including both companies R&D,the need for mutiple facilities, overlapping functions, etc. This was a smart move by both companies. DNDN is now stronger than ever. It has cash and a diversified pipeline addressing major markets. I can see oppotunities to out-license programs that neither company could do before the merger. The CVAS programs or the DNDN programs will have to be evaluated. The result will be additional cash.